MTND2P21: A Drug Target / Disease Biomarker (G100873227)

Target Name: MTND2P21

NCBI ID: G100873227

MTND2P21

Other Name(s): MT-ND2 pseudogene 21

MTND2P21: A Drug Target / Disease Biomarker

MTND2P21 is a drug target and a potential biomarker for the treatment of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Huntington's disease.

MTND2P21 is a protein that is expressed in the brain and is involved in the development and progression of these debilitating diseases. It is a key regulator of the tau protein, which is a protein that is involved in the formation of beta-amyloid plaques, a hallmark of Alzheimer's disease. MTND2P21 has also been shown to be involved in the formation of neurofibrillary tangles, another hallmark of Parkinson's disease.

Studies have shown thatMTND2P21 is highly expressed in the brain and that it is involved in the development and progression of neurodegenerative diseases. In addition, MTND2P21 has been shown to be involved in the formation of beta-amyloid plaques and neurofibrillary tangles, which are hallmarks of Alzheimer's disease and Parkinson's disease, respectively.

Because of its involvement in these diseases, MTND2P21 has been identified as a potential drug target. Researchers are currently working to develop compounds that can inhibit the activity of MTND2P21 and prevent the formation of beta-amyloid plaques and neurofibrillary tangles. These compounds may be used to treat neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

In addition to its potential as a drug target, MTND2P21 has also been identified as a potential biomarker for these diseases. The ability to detect and measure the level of MTND2P21 in the brain could be used as a diagnostic tool for neurodegenerative diseases. In addition, the ability to measure the level of MTND2P21 in the brain could be used as a monitoring tool to determine the effectiveness of treatments for these diseases.

Overall, MTND2P21 is a protein that is involved in the development and progression of neurodegenerative diseases. Its potential as a drug target and as a biomarker makes it an important area of research for the development of new treatments for these diseases. Further studies are needed to fully understand the role of MTND2P21 in these diseases and to develop effective treatments.

Protein Name: MT-ND2 Pseudogene 21

The "MTND2P21 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MTND2P21 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets